Compare companies
| Kronos Bio, Inc. | Gilead Sciences | Amgen | ||||
|---|---|---|---|---|---|---|
| Capitalization | ||||||
| Price | 0.9397 | 113.99 | 312.5 | |||
| Price priv. | ||||||
| Number of shares, million | 57.74 | 1258 | 538 | |||
| Capitalization, billion | 0.084 | 94.55 | 140.05 | |||
| EBITDA, billion | -0.114 | 7.61 | 7.9 | |||
| EV, billion | 0.0373 | 119.11 | 206.55 | |||
| Profit and loss report | ||||||
| Net profit, billion | -0.1127 | 5.67 | 6.72 | |||
| Revenue, billion | 0.0063 | 27.12 | 28.19 | |||
| EPS | -1.95 | 4.5 | 12.49 | |||
| Balance | ||||||
| Assets, billion | 0.2133 | 62.13 | 97.15 | |||
| Debt, billion | 0.0283 | 24.99 | 64.61 | |||
| Balance cost, billion | 0.1591 | 22.75 | 6.23 | |||
| Cash, billion | 0.0643 | 6.09 | 10.94 | |||
| Coefficients | ||||||
| Dividend yield, % | 0 | 3.65 | 2.91 | |||
| Dividend | 0 | 3.87 | 9.13 | |||
| Dividend yield priv., % | 0 | 0 | 0 | |||
| Dividend priv. | 0 | 0 | 0 | |||
| Dividends/profit, % | 0 | 67.24 | 67.83 | |||
| P/S | 11.66 | 3.7 | 5.42 | |||
| P/BV | 0.461 | 4.41 | 24.53 | |||
| P/E | 0 | 17.69 | 22.76 | |||
| Ev/Ebitda | -0.327 | 15.66 | 26.16 | |||
| Debt/Ebitda | -0.248 | 3.29 | 8.18 | |||
| Efficiency | ||||||
| ROE | -70.83 | 24.9 | 107.78 | |||
| ROA | -52.83 | 9.12 | 6.91 | |||
| ROIC | -39.13 | 11.06 | 17 | |||
| Ebitda margin | -1813.2 | 28.05 | 28.01 | |||
| Net margin | -1791.87 | 20.89 | 23.83 | |||
| Momentum | ||||||
| 1 week, price changes | -1.8 % | -1.77 % | -1.67 % | |||
| 1 month, price changes | -2.9 % | +18.57 % | +5.34 % | |||
| 3 months, price changes | -6.03 % | +23.39 % | +14.03 % | |||
| 6 months, price changes | -1.08 % | +37.65 % | -6 % | |||
| 1 year, price changes | -17.57 % | +53.6 % | +15.08 % | |||
| 3 years, price changes | -88.48 % | +79.23 % | +21.15 % | |||
| 5 years, price changes | +101.22 % | +40.18 % | ||||
| 10 years, price changes | +39.37 % | +101.9 % | ||||
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
